Business Description
Protagonist Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74366E1029
Description
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 299.4 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 39.49 | |||||
| Beneish M-Score | 78.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.3 | |||||
| 3-Year EBITDA Growth Rate | 3.8 | |||||
| 3-Year EPS without NRI Growth Rate | 10 | |||||
| 3-Year FCF Growth Rate | 16.2 | |||||
| 3-Year Book Growth Rate | -3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.88 | |||||
| 9-Day RSI | 36.53 | |||||
| 14-Day RSI | 38.14 | |||||
| 6-1 Month Momentum % | 97.04 | |||||
| 12-1 Month Momentum % | 20.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.71 | |||||
| Quick Ratio | 16.71 | |||||
| Cash Ratio | 16.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | -8.85 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -156.09 | |||||
| Net Margin % | -131.59 | |||||
| FCF Margin % | -118.08 | |||||
| ROE % | -28.93 | |||||
| ROA % | -26.38 | |||||
| ROIC % | -890.03 | |||||
| ROC (Joel Greenblatt) % | -2771.26 | |||||
| ROCE % | -34.27 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 14.31 | |||||
| PS Ratio | 25.94 | |||||
| PB Ratio | 4.42 | |||||
| Price-to-Tangible-Book | 4.42 | |||||
| EV-to-EBIT | -12 | |||||
| EV-to-EBITDA | -12.44 | |||||
| EV-to-Revenue | 18.72 | |||||
| EV-to-Forward-Revenue | 3.75 | |||||
| EV-to-FCF | -15.88 | |||||
| Price-to-Net-Current-Asset-Value | 4.45 | |||||
| Price-to-Net-Cash | 4.65 | |||||
| Earnings Yield (Greenblatt) % | -8.33 | |||||
| FCF Yield % | -4.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PTGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protagonist Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 60 | ||
| EPS (TTM) ($) | -1.49 | ||
| Beta | 2.62 | ||
| Volatility % | 60.18 | ||
| 14-Day RSI | 38.14 | ||
| 14-Day ATR ($) | 1.133459 | ||
| 20-Day SMA ($) | 26.8925 | ||
| 12-1 Month Momentum % | 20.38 | ||
| 52-Week Range ($) | 13.72 - 33.34 | ||
| Shares Outstanding (Mil) | 58.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protagonist Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protagonist Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Protagonist Therapeutics Inc Frequently Asked Questions
What is Protagonist Therapeutics Inc(PTGX)'s stock price today?
The current price of PTGX is $25.76. The 52 week high of PTGX is $33.34 and 52 week low is $13.72.
When is next earnings date of Protagonist Therapeutics Inc(PTGX)?
The next earnings date of Protagonist Therapeutics Inc(PTGX) is 2024-05-03 Est..
Does Protagonist Therapeutics Inc(PTGX) pay dividends? If so, how much?
Protagonist Therapeutics Inc(PTGX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers